National Collaborative for Innovation in Quality Measurement

Metabolic Monitoring for Children and Adolescents on Antipsychotics

Administrative Specification for State Reporting………………………………..Page 2
Administrative Specification for Health Plan Reporting…………………………..Page 3
Administrative Specification – State Level

Measure Description
The percentage of children and adolescents 1 to 20 years of age who had two or more antipsychotic prescriptions and had metabolic monitoring during the measurement year.

Note: A higher rate indicates better performance.

Eligible Population
Ages 1 to 20 years by December 31 of the measurement year. Report four age stratifications and a total rate.
- 1-5 years
- 6-11 years
- 12-17 years
- 18-20 years
- Total.

The total is the sum of the age stratifications.

Continuous Enrollment
At least 12 months.

Allowable Gap
No more than one gap in enrollment of up to 45 days during the measurement year.

Benefits
Medical and Pharmacy.

Event/diagnosis
At least two antipsychotic medication dispensing events (Table 1), regardless if they are the same or different medications, on different dates of service during the measurement year.

Numerator
Both of the following during the measurement year.
- At least one test for blood glucose (Glucose Tests Value Set) or HbA1c (HbA1c Tests Value Set)
- At least one tests for LDL-C (LDL-C Tests Value Set) or cholesterol (Cholesterol Tests Other than LDL Value Set).

Exclusions
None

Table 1. Antipsychotic Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Generation Antipsychotic Medications</td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine hcl</td>
<td>Molindone hcl</td>
</tr>
<tr>
<td>Fluphenazine hcl</td>
<td>Perphenazine</td>
</tr>
<tr>
<td>Fluphenazine decanoate</td>
<td>Pimozide</td>
</tr>
<tr>
<td>Fluphenazine enanthate</td>
<td>Promazine hcl</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>Thioridazine hcl</td>
</tr>
<tr>
<td>Haloperidol decanoate</td>
<td>Thiothixene</td>
</tr>
<tr>
<td>Haloperidol lactate</td>
<td>Thiothixene hcl</td>
</tr>
<tr>
<td>Loxapine hcl</td>
<td>Trifluoperazine hcl</td>
</tr>
<tr>
<td>Loxapine succinate</td>
<td>Triflupromazine hcl</td>
</tr>
</tbody>
</table>

| Second Generation Antipsychotic Medications |                                  |
| Aripiprazole                          | Paliperidone palmitate            |
| Clozapine                             | Quetiapine fumarate               |
| Iloperidone                           | Risperidone                       |
| Olanzapine                            | Risperidone microspheres          |
| Olanzapine pamoate                    | Ziprasidone hcl                   |
| Paliperidone                          | Ziprasidone mesylate              |

| Combinations                          |                                  |
| Olanzapine-fluoxetine hcl (Symbyax)   | Perphenazine-amitriptyline hcl (Etrafon, Triavil [various]) |
Administrative Specification – Health Plan Level

**Description**

The percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.

**Eligible Population**

<table>
<thead>
<tr>
<th>Product lines</th>
<th>Commercial, Medicaid (report each product line separately).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages</td>
<td>1 year of age to 17 years as of December 31 of the measurement year. Report three age stratifications and a total rate:</td>
</tr>
<tr>
<td></td>
<td>• 1–5 years.</td>
</tr>
<tr>
<td></td>
<td>• 6–11 years.</td>
</tr>
<tr>
<td></td>
<td>• 12–17 years.</td>
</tr>
<tr>
<td></td>
<td>• Total. The total is the sum of the age stratifications.</td>
</tr>
<tr>
<td>Continuous enrollment</td>
<td>The measurement year.</td>
</tr>
<tr>
<td>Allowable gap</td>
<td>No more than one gap in enrollment of up to 45 days during the measurement year.</td>
</tr>
<tr>
<td>Anchor date</td>
<td>December 31 of the measurement year.</td>
</tr>
<tr>
<td>Benefit</td>
<td>Medical and pharmacy.</td>
</tr>
<tr>
<td>Event/diagnosis</td>
<td>At least two antipsychotic medication dispensing events (Table XXX-A), regardless if they are the same or different medications, on different dates of service during the measurement year.</td>
</tr>
</tbody>
</table>

**Administrative Specification**

<table>
<thead>
<tr>
<th>Denominator</th>
<th>The eligible population.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numerator</td>
<td>Both of the following during the measurement year.</td>
</tr>
<tr>
<td></td>
<td>• At least one test for blood glucose (Glucose Tests Value Set) or HbA1c (HbA1c Tests Value Set).</td>
</tr>
<tr>
<td></td>
<td>• At least one test for LDL-C (LDL-C Tests Value Set) or cholesterol (Cholesterol Tests Other Than LDL Value Set).</td>
</tr>
</tbody>
</table>
### Table XXX-A. Antipsychotic Medications

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Generation Antipsychotic Medications</strong></td>
<td><strong>First Generation Antipsychotic Medications</strong></td>
</tr>
<tr>
<td>• Chlorpromazine hcl</td>
<td>• Molindone hcl</td>
</tr>
<tr>
<td>• Fluphenazine hcl</td>
<td>• Perphenazine</td>
</tr>
<tr>
<td>• Fluphenazine decanoate</td>
<td>• Pimozide</td>
</tr>
<tr>
<td>• Fluphenazine enanthate</td>
<td>• Promazine hcl</td>
</tr>
<tr>
<td>• Haloperidol</td>
<td>• Thioridazine hcl</td>
</tr>
<tr>
<td>• Haloperidol decanoate</td>
<td>• Thiothixene</td>
</tr>
<tr>
<td>• Haloperidol lactate</td>
<td>• Thiothixene hcl</td>
</tr>
<tr>
<td>• Loxapine hcl</td>
<td>• Trifluoperazine hcl</td>
</tr>
<tr>
<td>• Loxapine succinate</td>
<td>• Triflupromazine hcl</td>
</tr>
<tr>
<td><strong>Second Generation Antipsychotic Medications</strong></td>
<td><strong>Second Generation Antipsychotic Medications</strong></td>
</tr>
<tr>
<td>• Aripiprazole</td>
<td>• Paliperidone palmitate</td>
</tr>
<tr>
<td>• Clozapine</td>
<td>• Quetiapine fumarate</td>
</tr>
<tr>
<td>• Illoperidone</td>
<td>• Risperidone</td>
</tr>
<tr>
<td>• Olanzapine</td>
<td>• Risperidone microspheres</td>
</tr>
<tr>
<td>• Olanzapine pamoate</td>
<td>• Ziprasidone hcl</td>
</tr>
<tr>
<td>• Paliperidone</td>
<td>• Ziprasidone mesylate</td>
</tr>
<tr>
<td><strong>Combinations</strong></td>
<td><strong>Combinations</strong></td>
</tr>
<tr>
<td>• Olanzapine-fluoxetine hcl (Symbyax)</td>
<td>• Perphenazine-amitriptyline hcl (Etrafon, Triavl [various])</td>
</tr>
</tbody>
</table>

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 1, 2014.

### Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table XXX-1/2: Data Elements for Metabolic Monitoring for Children and Adolescents on Antipsychotics**

<table>
<thead>
<tr>
<th>Data Element</th>
<th>Administrative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measurement year</td>
<td>✓</td>
</tr>
<tr>
<td>Data collection methodology (Administrative)</td>
<td>✓</td>
</tr>
<tr>
<td>Eligible population</td>
<td>For each age stratification and total</td>
</tr>
<tr>
<td>Numerator events by administrative data</td>
<td>For each age stratification and total</td>
</tr>
<tr>
<td>Reported rate</td>
<td>For each age stratification and total</td>
</tr>
<tr>
<td>Lower 95% confidence interval</td>
<td>For each age stratification and total</td>
</tr>
<tr>
<td>Upper 95% confidence interval</td>
<td>For each age stratification and total</td>
</tr>
</tbody>
</table>